Inotek Pharmaceuticals Corp Company Profile (NASDAQ:ITEK)

About Inotek Pharmaceuticals Corp (NASDAQ:ITEK)

Inotek Pharmaceuticals Corp logoInotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ITEK
  • CUSIP: N/A
  • Web: www.inotekpharma.com
Capitalization:
  • Market Cap: $48.57 million
  • Outstanding Shares: 26,986,000
Average Prices:
  • 50 Day Moving Avg: $1.89
  • 200 Day Moving Avg: $3.12
  • 52 Week Range: $1.50 - $9.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.19
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.34 per share
  • Price / Book: 0.77
Profitability:
  • EBIDTA: ($41,520,000.00)
  • Return on Equity: -39.18%
  • Return on Assets: -33.28%
Debt:
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 23.39%
  • Quick Ratio: 23.39%
Misc:
  • Average Volume: 888,250 shs.
  • Beta: 3.38
  • Short Ratio: 2.77
 

Frequently Asked Questions for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)

What is Inotek Pharmaceuticals Corp's stock symbol?

Inotek Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "ITEK."

How were Inotek Pharmaceuticals Corp's earnings last quarter?

Inotek Pharmaceuticals Corp (NASDAQ:ITEK) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.01. View Inotek Pharmaceuticals Corp's Earnings History.

Where is Inotek Pharmaceuticals Corp's stock going? Where will Inotek Pharmaceuticals Corp's stock price be in 2017?

4 brokerages have issued twelve-month price targets for Inotek Pharmaceuticals Corp's shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Inotek Pharmaceuticals Corp's stock price to reach $5.75 in the next year. View Analyst Ratings for Inotek Pharmaceuticals Corp.

What are analysts saying about Inotek Pharmaceuticals Corp stock?

Here are some recent quotes from research analysts about Inotek Pharmaceuticals Corp stock:

  • 1. HC Wainwright analysts commented, "Phase 2 FDC data release narrowed to July. With the timing of Inotek’s Phase 2 fixed-dose combination (FDC) trial readout nearing, the company issued a release refining that window from mid-2017 to July, as enrollment for the study has now been completed. The market is not expecting a lot after the MATrX-1 study failed to beat placebo in January, but there is still a glimmer of hope for a positive outcome. Given the company’s enterprise value of negative $27M, we see a much stronger case for the upside (potential confirmation of efficacy with the more valuable, in our view, FDC product) versus limited downside." (4/12/2017)
  • 2. According to Zacks Investment Research, "Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts. " (1/17/2017)

Who are some of Inotek Pharmaceuticals Corp's key competitors?

When did Inotek Pharmaceuticals Corp IPO?

(ITEK) raised $40 million in an initial public offering (IPO) on Wednesday, February 18th 2015. The company issued 6,700,000 shares at $6.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Nomura were co-managers.

Who owns Inotek Pharmaceuticals Corp stock?

Inotek Pharmaceuticals Corp's stock is owned by many different of retail and institutional investors. Top institutional investors include RHO Capital Partners Inc. (9.74%), Vanguard Group Inc. (2.60%), Sphera Funds Management LTD. (1.49%), Columbus Circle Investors (1.43%), Sabby Management LLC (0.37%) and Morgan Stanley (0.25%). Company insiders that own Inotek Pharmaceuticals Corp stock include David P Southwell and J Martin Carroll. View Institutional Ownership Trends for Inotek Pharmaceuticals Corp.

Who sold Inotek Pharmaceuticals Corp stock? Who is selling Inotek Pharmaceuticals Corp stock?

Inotek Pharmaceuticals Corp's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Inotek Pharmaceuticals Corp.

Who bought Inotek Pharmaceuticals Corp stock? Who is buying Inotek Pharmaceuticals Corp stock?

Inotek Pharmaceuticals Corp's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Columbus Circle Investors, Minerva Advisors LLC, Goldman Sachs Group Inc. and Morgan Stanley. Company insiders that have bought Inotek Pharmaceuticals Corp stock in the last two years include David P Southwell and J Martin Carroll. View Insider Buying and Selling for Inotek Pharmaceuticals Corp.

How do I buy Inotek Pharmaceuticals Corp stock?

Shares of Inotek Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Inotek Pharmaceuticals Corp stock cost?

One share of Inotek Pharmaceuticals Corp stock can currently be purchased for approximately $1.80.

Analyst Ratings

Consensus Ratings for Inotek Pharmaceuticals Corp (NASDAQ:ITEK) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $5.75 (219.44% upside)

Analysts' Ratings History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017HC WainwrightReiterated RatingBuy$7.00LowView Rating Details
3/16/2017Canaccord GenuitySet Price TargetBuy$3.00MediumView Rating Details
1/3/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$3.00N/AView Rating Details
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
7/24/2015NomuraReiterated RatingBuy$13.00 -> $30.00N/AView Rating Details
7/24/2015Cowen and CompanyReiterated RatingOutperform$15.00 -> $40.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Earnings by Quarter for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Earnings History by Quarter for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.39)($0.40)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)($0.48)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.45)($0.41)ViewN/AView Earnings Details
8/10/2016Q2($0.40)($0.33)ViewN/AView Earnings Details
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.29)($0.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
2017 EPS Consensus Estimate: ($1.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.31)($0.31)($0.31)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Insider Ownership Percentage: 11.70%
Institutional Ownership Percentage: 81.49%
Insider Trades by Quarter for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Institutional Ownership by Quarter for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Insider Trades by Quarter for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2017David P. SouthwellInsiderBuy60,000$1.75$105,000.00View SEC Filing  
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.00View SEC Filing  
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Latest Headlines for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Inotek Pharmaceuticals Corp (ITEK)
www.americanbankingnews.com - May 12 at 4:05 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 11 at 7:52 PM
finance.yahoo.com logoInotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - May 10 at 6:14 PM
businesswire.com logoInotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and ... - Business Wire (press release)
www.businesswire.com - May 10 at 1:14 PM
marketbeat.com logoInotek Pharmaceuticals reports 1Q loss
marketbeat.com - May 10 at 7:28 AM
finance.yahoo.com logoInotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
finance.yahoo.com - May 8 at 5:38 PM
americanbankingnews.com logo-$0.35 Earnings Per Share Expected for Inotek Pharmaceuticals Corp (ITEK) This Quarter
www.americanbankingnews.com - May 3 at 4:08 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earning Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 3 at 10:44 AM
finance.yahoo.com logoKalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
finance.yahoo.com - May 2 at 10:38 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earns Media Impact Score of -0.12
www.americanbankingnews.com - April 30 at 11:39 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given Daily News Impact Rating of 0.19
www.americanbankingnews.com - April 28 at 12:10 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given Daily Media Sentiment Score of 0.37
www.americanbankingnews.com - April 23 at 4:21 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Getting Positive News Coverage, Report Shows
www.americanbankingnews.com - April 20 at 11:51 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 14 at 12:48 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - April 12 at 4:36 PM
finance.yahoo.com logoBlog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
finance.yahoo.com - April 12 at 8:59 AM
finance.yahoo.com logoInotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost
finance.yahoo.com - April 11 at 11:48 AM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 11 at 9:57 AM
finance.yahoo.com logoInotek Pharmaceuticals Financial Review Potential Value Drivers and Drug Pipeline
finance.yahoo.com - April 7 at 10:31 AM
americanbankingnews.com logo Inotek Pharmaceuticals Corp (ITEK) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 4 at 12:28 AM
finance.yahoo.com logoINOTEK PHARMACEUTICALS CORP Financials
finance.yahoo.com - March 22 at 6:11 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Given a $3.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 22 at 10:41 AM
seekingalpha.com logoInotek Pharmaceuticals Could Be Getting A Second Chance
seekingalpha.com - March 21 at 5:58 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) PT Set at $3.00 by Canaccord Genuity
www.americanbankingnews.com - March 18 at 12:10 PM
americanbankingnews.com logoInotek Pharmaceuticals Corp (ITEK) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 18 at 12:33 AM
finance.yahoo.com logoInotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights
finance.yahoo.com - March 16 at 6:50 PM
biz.yahoo.com logoINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 16 at 6:50 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
finance.yahoo.com - March 13 at 10:49 AM
globenewswire.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 5:33 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 - ITEK
finance.yahoo.com - March 6 at 5:33 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
finance.yahoo.com - March 6 at 5:33 PM
finance.yahoo.com logo24 HOUR DEADLINE NOTICE FOR ITEK INVESTORS: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 6 at 5:33 PM
finance.yahoo.com logoITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving …
finance.yahoo.com - March 3 at 5:57 PM
us.rd.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inotek Pharmaceuticals Corporation Investors and Encourages Investors to Contact the Firm
us.rd.yahoo.com - March 3 at 5:57 PM
feeds.benzinga.com logoITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
feeds.benzinga.com - March 3 at 12:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
finance.yahoo.com - March 1 at 11:37 AM
us.rd.yahoo.com logoInotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
us.rd.yahoo.com - February 27 at 6:38 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEK
feeds.benzinga.com - February 27 at 12:52 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - February 25 at 5:44 PM
streetinsider.com logoInotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society Meeting
www.streetinsider.com - February 25 at 12:20 AM
us.rd.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - February 25 at 12:20 AM
finance.yahoo.com logoURGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Immediately - ITEK
finance.yahoo.com - February 25 at 12:20 AM
streetinsider.com logoInotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society Meeting - StreetInsider.com
www.streetinsider.com - February 24 at 7:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Inotek Pharmaceuticals Corporation to Contact the Firm Before Lead Plaintiff Deadline
finance.yahoo.com - February 24 at 7:17 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - February 24 at 7:17 PM
businesswire.com logoInotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 ... - Business Wire (press release)
www.businesswire.com - February 24 at 10:11 AM
finance.yahoo.com logoInotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting
finance.yahoo.com - February 24 at 10:11 AM
finance.yahoo.com logoEQUITY NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - February 23 at 11:00 PM
feeds.benzinga.com logoIMPORTANT INOTEK INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of Massachusetts against Inotek Pharmaceuticals Corporation
feeds.benzinga.com - February 23 at 6:03 PM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7 ...
www.businesswire.com - February 22 at 12:32 PM

Social

Chart

Inotek Pharmaceuticals Corp (ITEK) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff